Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer.

"Declarations Conflict of interestMFB received research funding from Celgene. Prof. dr. Hanneke W. M. van Laarhoven has served as a consultant for Celgene, Lilly, Nordic, and Philips, and has received unrestricted research funding from Bayer, Celgene, Lilly, Merck, Serono, MSD, Nordic, Philips and Roche. None of these parties were involved in the current study. Ethical approvalThe medical ethical committee of the Amsterdam UMC, location AMC approved the collection of patient material in the BiOES prospective biobank of the Amsterdam UMC (AMC 2013_241) in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consentAll patients provided written informed consent to participate in the BiOES prospective biobank of the Amsterdam AUMC. Conflict of interest MFB received research funding from Celgene. Prof. dr. Hanneke W. M. van Laarhoven has served as a consultant for Celgene, Lilly, Nordic, and Philips, and has received unrestricted research funding from Bayer, Celgene, Lilly, Merck, Serono, MSD, Nordic, Philips and Roche. None of these parties were involved in the current study."

"Funding This study was conducted with funding from the Nijbakker Morra Stichting and De Jonge Akademie Projectbeurs."